An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
AiiM OLE
A Multicenter, Open-Label Extension Study of the Long-Term Safety of Vonaprument (ANX007) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy
2 other identifiers
interventional
605
1 country
7
Brief Summary
The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Sep 2026
Typical duration for phase_3
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 3, 2026
CompletedFirst Posted
Study publicly available on registry
September 8, 2026
CompletedStudy Start
First participant enrolled
September 30, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2029
September 8, 2026
September 1, 2026
2.8 years
September 3, 2026
September 3, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Number of Participants with Treatment Emergent Adverse Events
Through Month 24
Study Arms (1)
Vonaprument
EXPERIMENTALParticipants will receive vonaprument IVT injections every month for 24 months.
Interventions
Form: solution for injection; Route of Administration: IVT injection
Eligibility Criteria
You may qualify if:
- Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit.
You may not qualify if:
- Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Annexon, Inc.lead
Study Sites (7)
Retina Group of Florida
Sarasota, Florida, 34233, United States
Retina Vitreous Associates of Florida
St. Petersburg, Florida, 33711, United States
Cumberland Valley Retina Consultants
Hagerstown, Maryland, 21740, United States
Mid Atlantic Retina Specialists
Hagerstown, Maryland, 21740, United States
Retina Research Institute at New England Retina Consultants
Springfield, Massachusetts, 01107, United States
Asheville Eye Associates - Retina Division
Asheville, North Carolina, 28803, United States
Verum Research, LLC
Eugene, Oregon, 97401, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Trials
Annexon, Inc.
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 3, 2026
First Posted
September 8, 2026
Study Start
September 30, 2026
Primary Completion (Estimated)
July 31, 2029
Study Completion (Estimated)
July 31, 2029
Last Updated
September 8, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share